SCPH scPharmaceuticals
- 4.480
- -0.330-6.86%
- 4.570
- +0.090+2.01%
scPharmaceuticals News
ScPharmaceuticals to Announce First Quarter 2024 Financial Results On Tuesday, May 14, 2024
Management to host conference call and webcast at 4:30 p.m. ETBURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developin
Craig-Hallum Remains a Buy on ScPharmaceuticals (SCPH)
ScPharmaceuticals Enrolls First Participant In Pivotal Pharmacokinetic Study Of FUROSCIX Auto-Injector Injection
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body InfusorCompany anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 20
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersProtara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. Candel Therapeutics (N
Buy Rating Affirmed for ScPharmaceuticals Amidst Revenue Surge and Solid Financial Footing
HC Wainwright & Co. Reiterates Buy on ScPharmaceuticals, Maintains $18 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates scPharmaceuticals with a Buy and maintains $18 price target.
ScPharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/14/2024 229.07% HC Wainwright & Co. → $18 Reiterates Buy → Buy 09/07/2023 265.63% Craig-Hallum → $20 In
Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and ScPharmaceuticals (SCPH)
Strong Buy Recommendation for ScPharmaceuticals on Furoscix's Successful Launch and Growth Prospects
ScPharmaceuticals Inc (SCPH) Reports Q4 and Full-Year 2023 Financials, Focusing on FUROSCIX Growth
ScPharmaceuticals Files for $200M Mixed Shelf Offering
ScPharmaceuticals GAAP EPS of -$0.35 Beats by $0.07, Revenue of $6.1M Beats by $0.33M
ScPharmaceuticals 4Q Loss/Shr 35c >SCPH
ScPharmaceuticals 4Q Loss/Shr 35c >SCPH
Press Release: ScPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided a business update.
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. • Silence Therapeutics (NASDAQ:SLN) is expec
ScPharmaceuticals Q4 2023 Earnings Preview
A Preview Of ScPharmaceuticals's Earnings
scPharmaceuticals (NASDAQ:SCPH) is set to give its latest quarterly earnings report on Wednesday, 2024-03-13. Here's what investors need to know before the announcement.Analysts estimate that scPharma
Craig-Hallum Reaffirms Their Buy Rating on ScPharmaceuticals (SCPH)
ScPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024
BURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies,
ScPharmaceuticals to Participate in Two Upcoming Investor Conferences
BURLINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of
Analysis
Price Target
No Data
